

Amber M Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10765693/publications.pdf>

Version: 2024-02-01

26
papers

1,602
citations

471509

17
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

2098
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of the 1918 Influenza A Virus PB1-F2 Enhances the Pathogenesis of Viral and Secondary Bacterial Pneumonia. <i>Cell Host and Microbe</i> , 2007, 2, 240-249.	11.0	355
2	Kinetics of Coinfection with Influenza A Virus and <i>Streptococcus pneumoniae</i> . <i>PLoS Pathogens</i> , 2013, 9, e1003238.	4.7	184
3	Influenza A virus infection kinetics: quantitative data and models. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011, 3, 429-445.	6.6	136
4	Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. <i>Journal of Theoretical Biology</i> , 2011, 276, 106-116.	1.7	104
5	Secondary Bacterial Infections in Influenza Virus Infection Pathogenesis. <i>Current Topics in Microbiology and Immunology</i> , 2014, 385, 327-356.	1.1	104
6	An accurate two-phase approximate solution to an acute viral infection model. <i>Journal of Mathematical Biology</i> , 2010, 60, 711-726.	1.9	75
7	Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. <i>PLoS Computational Biology</i> , 2011, 7, e1001081.	3.2	67
8	Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling. <i>Immunological Reviews</i> , 2018, 285, 97-112.	6.0	65
9	COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. <i>PLoS Pathogens</i> , 2021, 17, e1009753.	4.7	61
10	A Critical, Nonlinear Threshold Dictates Bacterial Invasion and Initial Kinetics During Influenza. <i>Scientific Reports</i> , 2016, 6, 38703.	3.3	50
11	Modeling the Viral Dynamics of Influenza A Virus Infection. <i>Critical Reviews in Immunology</i> , 2010, 30, 291-298.	0.5	47
12	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel <i>Plasmodium falciparum</i> ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 964-975.	9.1	47
13	Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral Decay. <i>Frontiers in Microbiology</i> , 2018, 9, 1554.	3.5	45
14	Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity. <i>ELife</i> , 2021, 10, .	6.0	34
15	The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza. <i>Viral Immunology</i> , 2018, 31, 159-173.	1.3	28
16	Enhanced IL-1 β production is mediated by a TLR2-MYD88-NLRP3 signaling axis during coinfection with influenza A virus and <i>Streptococcus pneumoniae</i> . <i>PLoS ONE</i> , 2019, 14, e0212236.	2.5	26
17	Validated models of immune response to virus infection. <i>Current Opinion in Systems Biology</i> , 2018, 12, 46-52.	2.6	20
18	Leveraging Computational Modeling to Understand Infectious Diseases. <i>Current Pathobiology Reports</i> , 2020, 8, 149-161.	3.4	19

#	ARTICLE	IF	CITATIONS
19	Molecular signatures of virulence in the PB1-F2 proteins of H5N1 influenza viruses. <i>Virus Research</i> , 2013, 178, 146-150.	2.2	16
20	Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 81-93.	1.8	13
21	Effect of Vitamin A Deficiency in Dysregulating Immune Responses to Influenza Virus and Increasing Mortality Rates After Bacterial Coinfections. <i>Journal of Infectious Diseases</i> , 2021, 223, 1806-1816.	4.0	13
22	Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infections During SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	11
23	Parameter and Uncertainty Estimation for Dynamical Systems Using Surrogate Stochastic Processes. <i>SIAM Journal of Scientific Computing</i> , 2019, 41, A2212-A2238.	2.8	8
24	Dynamic Pneumococcal Genetic Adaptations Support Bacterial Growth and Inflammation during Coinfection with Influenza. <i>Infection and Immunity</i> , 2021, 89, e0002321.	2.2	6
25	Quantifying dose-, strain-, and tissue-specific kinetics of parainfluenza virus infection. <i>PLoS Computational Biology</i> , 2021, 17, e1009299.	3.2	5
26	Combining SJ733, an oral ATP4 inhibitor of <i>Plasmodium falciparum</i> , with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. <i>EBioMedicine</i> , 2022, 80, 104065.	6.1	4